Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: J Hepatol. 2013 Jan 16;58(5):949–955. doi: 10.1016/j.jhep.2013.01.003

Fig 1. Change in fecal secondary/primary bile acid concentration ratios after rifaximin therapy in early cirrhotic patients.

Fig 1

Figure 1a: LCA+DCA/CDCA+CA ratio, Figure 1b: LCA/CDCA ratio and Figure 1c: DCA/CA ratio change; there was a significant decrease in the fecal secondary to primary bile acid ratios after rifaximin therapy in early cirrhotic patients